Advertisement

Topics

Syneos Health Schedules First Quarter 2018 Earnings Call for Wednesday, May 9, 2018

20:00 EDT 16 Apr 2018 | Globe Newswire

RALEIGH, N.C., April 17, 2018 (GLOBE NEWSWIRE) -- Syneos HealthTM (Nasdaq:SYNH), the only fully integrated biopharmaceutical solutions organization combining a CRO and CCO (Contract Commercial Organization), will release its first quarter 2018 financial results on Wednesday, May 9, 2018, prior to its earnings call at 8:00 a.m. EDT. 

Participants may access the conference call live via webcast on the Investor Relations section of the Syneos Health website at investor.syneoshealth.com. To participate via telephone, please dial +1 877 930 8058 within the United States or +1 253 336 7551 outside the United States, approximately 15 minutes prior to the scheduled start time. The conference ID for the call is 6394229.

A webcast replay will be available on the Investor Relations section of the Syneos Health website at investor.syneoshealth.com after 1:00 p.m. on May 9. In addition, an audio replay will be available for one week following the call and will be accessible by dialing +1 855 859 2056 within the United States or +1 404 537 3406 outside the United States. The replay ID is 6394229.

About Syneos Health
Syneos Health (Nasdaq:SYNH) is the only fully integrated biopharmaceutical solutions organization. Our company, including a Contract Research Organization (CRO) and Contract Commercial Organization (CCO), is purpose-built to accelerate customer performance to address modern market realities. Created through the merger of two industry leading companies – INC Research and inVentiv Health – we bring together more than 21,000 clinical and commercial minds with the ability to support customers in more than 110 countries. Together we share insights, use the latest technologies and apply advanced business practices to speed our customers’ delivery of important therapies to patients. To learn more about how we are shortening the distance from lab to lifeTM visit syneoshealth.com.

        
Investor Relations Contact:          Press/Media Contact:
Ronnie Speight       Danielle DeForge
Vice President, Investor Relations     Senior Director, External Communications
+1 919 745 2745     +1 781 425 2624
investor.relations@syneoshealth.com    danielle.deforge@syneoshealth.com

Primary Logo

NEXT ARTICLE

More From BioPortfolio on "Syneos Health Schedules First Quarter 2018 Earnings Call for Wednesday, May 9, 2018"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Clinical Research Organization
Contract Research Organization (CRO) provide research services outsourced on a contract basis to the pharmaceutical, biotechnology, healthcare and medical device industries: biopharmaceutical development biologic assay development commercial...

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...